Insider Selling: Bioventus Inc. (NYSE:BVS) CFO Sells 9,219 Shares of Stock

Bioventus Inc. (NYSE:BVS) CFO Mark Leonard Singleton sold 9,219 shares of the stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $5.57, for a total transaction of $51,349.83. Following the sale, the chief financial officer now directly owns 84,895 shares of the company’s stock, valued at $472,865.15. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Mark Leonard Singleton also recently made the following trade(s):

• On Monday, June 17th, Mark Leonard Singleton sold 13,753 shares of Bioventus stock. The shares were sold at an average price of $5.84, for a total transaction of $80,317.52.
• On Thursday, April 11th, Mark Leonard Singleton sold 4,000 shares of Bioventus stock. The shares were sold at an average price of $4.75, for a total transaction of $19,000.00.

Bioventus Stock Down 2.0 %

BVS stock opened at $5.48 on Wednesday. The firm has a market capitalization of $433.85 million, a P/E ratio of -15.66 and a beta of 0.88. The company has a debt-to-equity ratio of 1.63, a current ratio of 1.53 and a quick ratio of 0.97. The company’s 50 day simple moving average is $5.63 and its 200-day simple moving average is $5.19. Bioventus Inc. has a 52-week low of $2.71 and a 52-week high of $7.04.

Bioventus (NYSE:BVS) last released its quarterly earnings data on Tuesday, May 7th. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.12. The firm had revenue of $129.46 million for the quarter, compared to analyst estimates of $115.51 million. Bioventus had a negative net margin of 4.14% and a positive return on equity of 11.91%. As a group, equities research analysts anticipate that Bioventus Inc. will post 0.27 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC acquired a new position in Bioventus in the 1st quarter valued at approximately $28,000. Lazard Asset Management LLC acquired a new position in Bioventus in the 1st quarter valued at approximately $40,000. SG Americas Securities LLC acquired a new position in Bioventus in the 1st quarter valued at approximately $66,000. Quadrature Capital Ltd acquired a new position in shares of Bioventus during the 4th quarter worth $85,000. Finally, GSG Advisors LLC acquired a new position in shares of Bioventus during the 4th quarter worth $89,000. Institutional investors and hedge funds own 62.94% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Canaccord Genuity Group boosted their price target on shares of Bioventus from $7.00 to $8.00 and gave the company a “buy” rating in a report on Wednesday, May 8th. Craig Hallum boosted their price target on shares of Bioventus from $6.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, March 13th.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.